chr10-43113628-G-T
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong
The NM_020975.6(RET):c.1832G>T(p.Cys611Phe) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. C611G) has been classified as Likely pathogenic.
Frequency
Consequence
NM_020975.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RET | NM_020975.6 | c.1832G>T | p.Cys611Phe | missense_variant | Exon 10 of 20 | ENST00000355710.8 | NP_066124.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1461072Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 726764
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Multiple endocrine neoplasia type 2A Pathogenic:1
- -
Multiple endocrine neoplasia, type 2 Pathogenic:1
This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Cys611 amino acid residue in RET. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9230192, 20979234, 27809725, 28099363). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 24899). This missense change has been observed in individual(s) with medullary thyroid carcinoma (PMID: 8626834, 11331212, 20979234). It has also been observed to segregate with disease in related individuals. This sequence change replaces cysteine, which is neutral and slightly polar, with phenylalanine, which is neutral and non-polar, at codon 611 of the RET protein (p.Cys611Phe). -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.C611F pathogenic mutation (also known as c.1832G>T), located in coding exon 10 of the RET gene, results from a G to T substitution at nucleotide position 1832. The cysteine at codon 611 is replaced by phenylalanine, an amino acid with highly dissimilar properties. Multiple mutations at codon 611 have been associated with Hirschsprung Disease (HSCR), Multiple Endocrine Neoplasia Type 2A (MEN2A), and Familial Medullary Thyroid Cancer (FMTC) (Eng C et al. JAMA. 1996 Nov;276:1575-9; Nishikawa M et al. Eur J Hum Genet. 2003 May;11(5):364-8). The p.C611F pathogenic mutation has been reported in numerous families diagnosed with MEN2A (Frank-Raue K et al. J. Clin. Endocrinol. Metab. 1996 May;81:1780-3; Siggelkow H et al. Eur. J. Endocrinol. 2001 May;144:467-73). The American Thyroid Association Guidelines Task Force has provided recommendations for individuals with RET gene mutations (Kloos et al. Thyroid. 2009 June; 19(6):565-612; Wells SA et al. Thyroid. 2015 Jun;25:567-610). This amino acid position is highly conserved in available vertebrate species. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is pathogenic for MEN2; however, the association of this alteration with Hirschsprung disease is unknown. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at